Abstract 535P
Background
Copy number alterations (CNAs) are common consequences of genome instability in lung cancer. Focal amplifications in NKX2-1 copy number (CN) have been frequently observed in non-small cell lung cancer (NSCLC). However, beyond CN gain, little is known about the complete landscape of NKX2-1 CNAs, their clinical significance, and their therapeutic implications in NSCLC.
Methods
Correlations of NKX2-1 expression with EGFR driver mutations and PD-L1 co-expression were studied using immunohistochemistry and PCR from tumors of recruited Filipino patients (n=45). Clinical features of NSCLC with NKX2-1 CNAs were resolved at the tumor and clonal levels using the molecular profiles of LUAD and LUSC participants from TCGA (n=1,130), and deconvoluted single-cell RNA-seq data from Bivona project (n=1,654), respectively.
Results
NKX2-1 expression and CN variations correlated significantly (r= 0.264; p<0.001). However, NKX2-1 CNAs exert a stronger influence on the combined EGFR and PD-L1 status of NSCLC tumors (p<0.05) than expression (p>0.05). NKX2-1 CN gain was prognostic of favorable survival (p=0.018), whereas, NKX2-1 CN loss prognosed worse survival (p=0.041). Mutational architecture in Y-chromosome differentiates the two prognostic groups. There were 19,941 synonymous mutations and 1,408 genome-wide CN perturbations associated with NKX2-1 CNAs. Tumors with NKX2-1 CN gain had higher B cell (p<0.001) and total T cell estimates (p=0.003). NKX2-1 CN loss was associated with colder tumors due to higher M2 macrophage infiltrates (p=0.011) and higher expression of immune checkpoint proteins, CD274 (p=0.025), VTCN1 (p<0.001), and LGALS9 (p=0.002). Lymphocyte marker signature in CN gain was prognostic of longer disease-free survival (p=0.005).
Conclusions
NKX2-1 CNAs are associated with tumors that exhibit clinically diverse characteristics, and with unique oncogenic, immunologic, and prognostic signatures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Science and Technology - Philippine Council for Health Research and Development.
Funding
Department of Science and Technology - Philippine Council on Health Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract